Related Experiment Video
Updated: Aug 4, 2025
A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
Published on: March 25, 2014
An ultra-high-throughput screen for the evaluation of peptide HLA-Binder interactions
Stefan Krämer1, Andreas Moritz2, Luca Stehl3
1BioCopy GmbH, 79312, Emmendingen, Germany. stefan.kraemer@biocopy.de.
Abstract:
Peptide human leukocyte antigen (pHLA) targeting therapeutics like T-cell receptor based adoptive cell therapy or bispecific T cell engaging receptor molecules hold great promise for the treatment of cancer. Comprehensive pre-clinical screening of therapeutic candidates is important to ensure patient safety but is challenging because of the size of the potential off-target space. By combining stabilized peptide-receptive HLA molecules with microarray printing and screening, we have developed an ultra-high-throughput screening platform named ValidaTe that enables large scale evaluation of pHLA-binder interactions. We demonstrate its potential by measuring and analyzing over 30.000 binding curves for a high-affinity T cell Engaging Receptor towards a large pHLA library. Compared to a dataset obtained by conventional bio-layer interferometry measurements, we illustrate that a massively increased throughput (over 650 fold) is obtained by our microarray screening, paving the way for use in pre-clinical safety screening of pHLA-targeting drugs.
Insights
We developed ValidaTe, a high-throughput screening platform for evaluating peptide-human leukocyte antigen (pHLA) interactions. This method significantly accelerates pre-clinical safety screening for novel cancer therapeutics targeting pHLA.
Area of Science:
- Immunology
- Biotechnology
- Pharmacology
Background:
- Peptide-human leukocyte antigen (pHLA) targeting therapeutics, including T-cell receptor-based adoptive cell therapy and bispecific T cell engaging receptor molecules, show significant promise for cancer treatment.
- Comprehensive pre-clinical screening is crucial for ensuring the safety of these therapeutic candidates, but the vast potential off-target space presents a significant challenge.
- Current screening methods lack the throughput necessary for evaluating the extensive range of potential interactions.
Purpose of the Study:
- To develop an ultra-high-throughput screening platform for evaluating peptide-human leukocyte antigen (pHLA) binder interactions.
- To enable large-scale pre-clinical safety screening of pHLA-targeting cancer therapeutics.
- To significantly increase the efficiency of assessing therapeutic candidate interactions with pHLA targets.
Main Methods:
- Development of the ValidaTe platform by combining stabilized peptide-receptive HLA molecules with microarray printing and screening.
- Utilizing microarray technology for ultra-high-throughput screening of pHLA-binder interactions.
- Measuring and analyzing over 30,000 binding curves for a high-affinity T cell Engaging Receptor against a large pHLA library.
Main Results:
- Demonstrated the capability of the ValidaTe platform to perform large-scale evaluation of pHLA-binder interactions.
- Achieved an over 650-fold increase in throughput compared to conventional bio-layer interferometry measurements.
- Successfully measured and analyzed over 30,000 binding curves, providing comprehensive interaction data.
Conclusions:
- The ValidaTe platform offers a massively increased throughput for evaluating pHLA-binder interactions.
- This novel screening approach significantly enhances pre-clinical safety assessment for pHLA-targeting drugs.
- ValidaTe paves the way for more efficient and comprehensive safety evaluations in cancer therapeutic development.
